## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Confirmation No. 2676

Richard F. Ambinder

Group Art Unit: 1648

Application No. 10/528,311

Examiner: Bao Q. Li

Filed: March 24, 2006

For: CANCER IMMUNOTHERAPY WITH A VIRAL

ANTIGEN-DEFINED IMMUNOMODULATOR-

SECRETING CELL VACCINE

## RESPONSE TO RESTRICTION REQUIREMENT MAILED MARCH 25, 2008

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicant respectfully elects **Group I** (Claims 1-13 and 16-49) with traverse. For species, applicant elects "LMP-2 and GM-CSF". Applicant requests that Groups I and II be combined because the search terms and classifications are almost identical for these two groups and would not require undue burden on the examiner to search and examine claims for Groups I and II.

No fees are due. However, please charge any fees that might be due in connection with this submission to our Deposit Account No. 12-0913 with respect to our matter number 43369-103949.

Respectfully submitted,

Sendre Derados

Date: April 16, 2008 Sendil Devadas, Ph.D., J.D.

Reg. No. 52,425

**BARNES & THORNBURG LLP** 

P.O. Box 2786

Chicago, IL 60690-2786 Phone: 312-338-5921 Facsimile: 312-759-5646